Xichun Hu

机构：Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center · ORCID：0000-0001-6148-9186

发表论文 260 篇 · 总被引 4907 次 · h-index 37

代表论文

• Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer (2025 · New England Journal of Medicine · 被引 123)
• ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
• Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort (2025 · Nature Communications · 被引 15)
• Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. (2025 · Journal of Clinical Oncology · 被引 14)
• Chaperonin‐containing TCP1 subunit 6A inhibition via TRIM21‐mediated K48‐linked ubiquitination suppresses triple‐negative breast cancer progression through the AKT signalling pathway (2024 · Clinical and Translational Medicine · 被引 9)
• The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications (2025 · Biomarker Research · 被引 4)